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Background: Disability either due to illness, aging, or both causes remains an essential 
contributor shaping European labor markets. Ability of modern day welfare states to 
compensate an impaired work ability and absenteeism arising from incapacity is very 
diverse. The aims of this study were to establish and explain intercountry differences 
among selected European OECD countries and to provide forecasts of future work 
absenteeism and expenditures on wage replacement benefits.
Methods: Two major public registries, European health for all database and Organization 
for Economic Co-operation and Development database (OECD Health Data), were 
coupled to form a joint database on 12 core indicators. These were related to disability, 
work absenteeism, and sickness benefits in European OECD countries. Time horizon 
1989–2013 was observed. Forecasting analysis was done on mean values of all data for 
each single variable for all observed countries in a single year. Trends were predicted on 
a selected time horizon based on the mean value, in our case, 7 years up to 2020. For 
this purpose, ARIMA prediction model was applied, and its significance was assessed 
using Ljung–Box Q test.
results: Our forecasts based on ARIMA modeling of available data indicate that up 
to 2020, most European countries will experience downfall of absenteeism from work 
due to illness. The number of citizens receiving social/disability benefits and the number 
being compensated due to health-related absence from work will decline. As opposed 
to these trends, cancer morbidity may become the top ranked disability driver as hospital 
discharge diagnoses. Concerning development is the anticipated bold growth of hos-
pital discharge frequencies due to cancer across the region. This effectively means that 
part of these savings on social support expenditure shall effectively be spent to combat 
strong cancer morbidity as the major driver of disability.
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inTrODUcTiOn
Permanent or temporary medically confirmed disability has 
increasingly become a matter of public attention throughout 
Europe (1). Policy makers are more aware of its far-reaching 
consequences in terms of demand for hospital and long-term 
home medical care (2). Another concerning issue is labor market 
participation. In the environment of accelerated population, aging 
labor force is shrinking in majority of industrialized northern 
hemisphere nations (3). Thus, there are ever-growing pressure for 
harsher social policies, extension of working life in both gender, 
and inclusion of people with a disability into the labor market. 
Flexible and generous early retirement policies and disability 
pensions may become something that belonged in the past in a 
few decades (4). Although there is large number of evidence on 
these issues forecasts on transnational European trends are far 
more scarce (5). The authors try to fill the knowledge gap about 
disability, work absenteeism, and sickness benefits in selected 
European OECD countries in relation to cancer morbidity and 
hospital workload. Thus, this study aims to explain intercountry 
differences among selected European OECD countries and pro-




Two major public registries, World Health Organization (WHO) 
that issued European health for all database (HFA-DB) (6) and 
Organization for Economic Co-operation and Development 
database OECD Health Data (OECD Health), were coupled to 
form a joint database on 12 core indicators (6, 7). These indica-
tors were related to disability, work absenteeism, and sickness 
benefits in European OECD countries. Time horizon 1989–2013 
was adopted.
Forecasting analysis is the process of making predictions of 
the future based on past and present data and analysis of trends 
(8). Forecasting analysis was performed based on the available 
data for selected countries. Countries entered into the analysis 
differed depending on data availability since the body of compa-
rable transnational evidence has a “Swiss cheese”-shaped, hollow 
distribution with significant amount of missing data (9). This was 
the case due to diverse policies of national authorities reporting 
to the relevant WHO and OECD bodies in a given historical 
period.
The 12 indicators for this analysis were selected from the com-
plete list of available indicators, because only these ones could be 
subject to forecasting analysis due to large number of missing val-
ues for other indicators. Therefore, countries observed for “absen-
teeism from work due to illness” indicator (days per employee 
per year; source: HFA-DB) were Austria, Czech Republic, 
Hungary, Netherlands, and Slovenia. For indicator number of 
“people receiving social/disability benefits per 100,000” (source: 
HFA-DB), observed countries were Austria, Czech Republic, 
Estonia, Finland, Hungary, Israel, Netherlands, Norway, Slovakia, 
Sweden, and Switzerland. For indicator “hospital discharges due 
to cancer” (source: HFA-DB), observed countries were Austria, 
Czech Republic, Denmark, Estonia, Finland, Greece, Hungary, 
Italy, Netherlands, Norway, Portugal, Slovenia, Slovakia, Spain, 
Sweden, and Turkey. For indicator “public expenditure on 
incapacity%GDP” (disability + sickness benefits; source: OECD 
Health Data), observed countries were Austria, Czech Republic, 
France, Hungary, Luxembourg, Netherlands, Slovenia, Sweden, 
and United Kingdom. For indicator “compensated absence from 
work due to illness” (source: OECD Health Data), observed 
countries were Austria, Belgium, Czech Republic, Denmark, 
Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, 
Netherlands, Norway, Poland, Portugal, Spain, Sweden, 
Switzerland, Turkey, and United Kingdom.
Data analysis
Forecasting analysis was done on mean values of all data for each 
single variable for all observed countries in a single year. On the 
basis of that mean value trend 1989–2013, we predicted on a 
selected time horizon, in our case 7 years (2014–2020), how this 
variable is likely to behave in the future. For this purpose, ARIMA 
prediction modeling was applied, and its significance was assessed 
using Ljung–Box Q test.1 This test says that if “p” is greater than 
0.05, it means that the model is correctly specified. In our sample, 
p values using Ljung–Box Q test for the five selected variables 
in the order of appearance are p = 0.782, p = 0.819, p = 0.232, 
p = 0.907, and p = 0.353: associated with absenteeism from work 
1 Ljung-Box Statistics for ARIMA Residuals in R. Available from: http://stats.
stackexchange.com/questions/64711/ljung-box-statistics-for-arima-residuals-in- 
r-confusing-test-results.
conclusion: We have clearly growing work load for the national health systems attrib-
utable to the clinical oncology acting as the major disability contributor. This effectively 
means that large share of these savings on public expenditure shall effectively be spent 
to combat strong cancer morbidity. On another side, we have all signs of falling societal 
responsibility toward the citizens suffering from diverse kinds of incapacity or impaired 
working ability and independence. Citizens suffering from any of these causes are likely 
to experience progressively less social support and publicly funded care and work sup-
port compared to the golden welfare era of previous decades.
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hFa-DB hospital discharges, 
all neoplasms per 100,000
Austria 12.4 (11.7–12.6) 4,646.4 (4,441.1–4,925.3) – 70.0 (67.1–72.6) 322.5 (267.9–333.0) 2,572.8 (2,397.5–2,673.2)
Belgium 7.2 (7.0–7.4) 2,096.0 (2,088.0–2,405.6) – 71.0 (67.0–72.7) – 1,243.6 (1,223.7–1,263.3)
Czech Republic 21.1 (18.2–21.3) 5,065.1 (4,812.5–5,200.1) 22.4 (15.7–24.6) 69.0 (64.2–71.4) 436.4 (385.8–450.2) 1,905.9 (1,751.3–1,920.8)
Denmark 8.3 (8.1–8.6) 3,295.3 (3,307.4–3,683.8) – 70.0 (66.6–72.1) – 1,886.6 (1,874.1–2,027.0)
Estonia 9.3 (8.8–9.9) 6,794.3 (5,306.4–7,595.7) 22.4 (19.2–26.1) 67.0 (58.3–72.2) 1,257.5 
(912.3–1,664.5)
1,136.8 (930.9–1,168.5)
Finland 7.8 (7.6–8.2) 5,401.0 (5,425.1–5,845.9) 3.9 (3.8–4.1) 71.0 (67.1–73.1) 538.2 (508.3–585.1) 2,209.9 (2,067.5–2,317.8)
France – 441.4 (421.8–451.8) – 72.0 (67.8–74.1) – 2,035.7 (1,993.1–2,103.4)
Germany 16.4 (15.3–17.0) 8,116.2 (7,794.8–8,612.6) 4.2 (4.0–4.2) 71.0 (67.2–73.4) 218.3 (224.3–279.1) 2,296.4 (2,176.9–2,348.4)
Greece – 748.7 (691.1–1,010.1) – 71.0 (67.4–73.4) – 1,444.8 (1,368.0–1,638.3)
Hungary 14.9 (13.2–17.3) 6,547.3 (5,641.6–6,551.9) 9.5 (8.2–9.5) 65.0 (60.0–67.9) 420.0 (364.8–481.0) 2,421.8 (1,925.4–2,495.7)
Ireland – 3,545.1 (3,245.7–3,592.1) 31.2 71.0 (65.3–74.5) 147.5 (128.4–408.3) 822.1 (814.1–838.8)
Israel 4.1 (3.9–4.4) 3,066.6 (2,822.2–3,248.3) 13.5 (11.2–15.5) 72.0 (66.8–75.3) 328.3 (312.0–343.1) 785.2 (732.5–810.3)
Italy – 2,181.1 (2,056.0–2,633.4) 16.3 (15.0–16.6) 73.0 (68.3–75.6) 860.1 (728.5–902.1) 1,397.2 (1,360.7–1,480.8)
Luxembourg 9.9 (9.2–10.3) 3,090.6 (2,435.1–3,746.1) – 71.0 (66.5–74.6) – 1,732.6 (1,659.5–1,969.9)
Netherlands 12.0 (11.9–13.9) 5,655.3 (5,291.3–5,735.3) 33.5 (31.2–36.5) 71.0 (67.2–73.7) – 947.0 (927.6–977.6)
Norway 17.3 (17.0–18.1) 6,103.5 (5,802.6–6,151.2) 43.1 (35.7–46.3) 71.0 (66.4–73.1) 631.5 (593.6–668.6) 1,756.4 (1,706.3–1,773.5)
Poland 12.3 (8.2–12.0) 8,776.8 (7,908.6–9,176.2) 20.8 (19.5–21.5) 67.0 (62.7–69.6) 157.2 (139.0–229.0) 1,147.5 (1,127.4–1,668.3)
Portugal 13.0 (10.8–14.7) 3,421.1 – 71.0 (65.1–74.3) – 780.2 (733.9–882.7)
Slovak Republic 30.9 (26.2–37.0) 5,167.6 (4,433.0–5,042.5) 24.1 (9.6–25.6) 67.0 (62.0–69.5) 329.9 (311.6–383.5) 1,571.7 (1,490.5–1,632.2)
Slovenia 13.8 (13.0–14.4) – 1.0 (0.8–1.2) 69.0 (63.4–73.0) 380.5 (339.4–387.3) 1,652.2 (1,503.5–1,678.3)
Spain 12.9 (7.4–17.7) 497.6 (472.7–525.8) 27.2 (24.7–28.4) 73.0 (68.5–75.9) 364.0 (321.6–416.9) 882.3 (792.1–884.3)
Sweden 20.0 (18.5–22.5) 4,763.5 (4,652.8–5,232.8) 44.0 72.0 (68.6–73.5) 530.5 (415.7–575.3) 1,654.1 (1,562.4–1,770.3)
Switzerland – 2,847.5 (2,512.5–2,925.1) 41.7 72.0 (68.4–74.6) 305.3 (249.5–307.8) 1,113.2 (1,074.2–1,197.5)
Turkey 3.4 (2.6–4.0) 9,956.7 (9,191.4–10,781.9) 21.7 65.0 (56.9–70.4) – 351.1 (308.0–491.9)
United Kingdom 1.1 (1.0–1.2) – – 70.0 (66.5–72.9) – 995.5 (966.9–1,015.8)
Kruskal–Wallis 
test
p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
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due to illness (days per employee per year) (6), people receiving 
social/disability benefits per 100,000 (6), hospital discharges due 
to cancer 1989–2013 (6), public expenditure on incapacity%GDP 
(disability +  sickness benefits; OECD Data), and compensated 
absence from work due to illness (OECD Data), respectively.
In Tables  1 and 2, values of health indicators are shown as 
medians, and statistical significance between selected countries 
for each indicator individually was analyzed using non-paramet-
ric Kruskal–Wallis test.
resUlTs
Our forecasts based on ARIMA modeling of available data 
indicate that up to 2020, most European countries will experi-
ence a downward trend of absenteeism from work due to illness 
(Figure 1A) and as will the number of citizens receiving social/
disability benefits and compensated absence from work due to 
illness (Figures 1B,D). Opposed to this, cancer morbidity may 
become a top ranked disability driver and thereby cause a bold 
growth in hospital discharges due to cancer (Figure 1C). Public 
expenditure on incapacity expressed as percentage point share of 
GDP (disability + sickness benefits observed) remains unknown 
in current analysis due to large variations and unpredictability 
(Figure 1E).
More details on each of five prominent indicators (each 
one reflecting slightly different group of nations) can be found 
in Figure  1, presenting forecasting analysis with actual data 
1989–2013 and time horizon up to 2020. Individual median 
annual values for all the selected indicators referring to coun-
tries observed can be found in Tables 1 and 2, on time horizon 
1989–2013.
DiscUssiOn
Of extracted data, we can observe great transnational variability 
of most indicators depicting disability burden in the European 
region (10). Significant part of this diversity is attributable to the 
traditional historical differences in welfare legacies in European 
TaBle 2 | Median (95% confidence interval) national values of selected indicators per each country for the period 1989–2013 based on health for all 
database (hFa-DB) and Organization for economic co-operation and Development (OecD) health Data sources.
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Disability benefits per 
100,000
Austria 453.5 (435.4–455.8) 3.4 (3.2–3.6) – 12.4 (11.7–12.6) 2.7 (2.5–2.7) 3,466.2 (3,381.9–3,511.9)
Belgium 467.5 (409.4–504.8) – – 9.3 (8.4–10.2) 2.7 (2.5–2.8) 4,582.3 (3,805.4–5,342.9)
Czech Republic 601.0 (570.6–674.5) 3.0 (2.7–3.6) 8.3 21.1 (18.2–21.3) 2.3 (2.2–2.4) 4,081.0 (3,877.7–4,184.6)
Denmark 517.0 (518.7–585.2) 3.5 (3.4–3.8) 6.9 (6.4–8.00) 8.4 (8.3–8.8) 3.8 (3.7–4.2) 1,907.7 (281.5–3,607.2)
Estonia 431.7 (406.6–480.9) 2.4 (2.1–2.7) 8.3 (7.4–9.1) 9.3 (8.8–9.9) 1.8 (1.7–2.1) 6,353.6 (5,622.9–7,209.4)
Finland 453.8 (431.7–488.5) 3.0 (2.7–3.5) 8.4 (8.1–8.7) – 4.1 (4.0–4.5) 4,941.0 (4,697.7–5,092.7)
France 523.6 (429.8–571.4) 1.3 (0.8–1.8) 9.0 8.0 (7.8–8.2) 1.9 (1.8–2.02) 3,945.7 (3,857.9–4,006.9)
Germany 501.8 (474.2–527.0) 1.7 (1.6–1.8) – 16.4 (15.5–17.1) 2.1 (2.0–2.2) 1,035.5 (1,021.0–1,071.9)
Greece – 0.9 (0.6–1.2) 14.8 3.6 (3.4–3.7) 0.9 (0.9–1.1) 1,283.3 (1,153.6–1,331.8)
Hungary 805.9 (510.8–778.8) – 8.3 (2.7–12.9) 14.9 (13.2–17.3) 2.7 (2.5–2.8) 3,793.3 (3,083.4–4,410.3)
Ireland 384.2 (364.9–399.1) 2.5 – 16.9 1.7 (1.6–1.9) 3,384.0 (3,323.7–3,442.7)
Israel 343.8 (317.0–343.8) 1.1 (0.9–1.1) 4.1 (3.8–4.3) – 2.8 (2.5–2.9) –
Italy 510.0 (470.5–519.0) 3.0 (2.8–3.4) 5.8 (4.5–7.1) – 1.8 (1.7–1.9) 1,602.5 (1,563.9–1,639.4)
Luxembourg 423.6 (398.8–429.5) – – 11.2 (10.6–11.6) 3.1 (3.0–3.2) 3,576.4 (3,541.8–3,645.8)
Netherlands 493.9 (487.3–565.6) 2.5 (2.3–2.7) – 12.0 (11.9–13.9) 3.9 (3.8–4.8) 937.7 (802.0–1,235.7)
Norway 498.9 (479.8–524.4) 3.4 (3.1–3.6) – 17.3 (16.9–18.1) 4.7 (4.9–4.8) 6,169.5 (6,007.3–6,713.6)
Poland 300.8 (281.9–325.6) – 6.7 – 3.4 (3.3–4.6) 4,095.7 (3,867.6–4,613.4)
Portugal 318.9 (265.6–363.8) 1.9 6.3 – 2.2 (2.2–2.3) 3,769.5 (3,563.2–3,962.0)
Slovak Republic 399.9 (386.8–443.5) 0.4 (0.4–0.4) – 13.9 (12.4–14.9) 2.0 (1.8–2.1) 3,998.2 (3,713.2–4,367.6)
Slovenia 459.2 (429.1–519.6) 2.4 (2.2–2.9) 12.9 13.8 (13.0–14.4) 2.4 (2.3–2.6) 2,035.6 (1,849.5–2,173.5)
Spain – – 9.2 10.5 (8.9–11.0) 2.5 (2.4–2.5) 2,475.7 (2,452.6–2,493.9)
Sweden 530.1 (518.0–563.5) 4.5 (4.3–4.8) – 13.3 (11.4–15.1) 5.1 (4.9–5.3) 5,176.5 (4,336.8–5,959.3)
Switzerland 463.4 (443.3–468.3) – 7.7 (6.9–8.6) – 2.6 (2.4–2.8) 5,000.4 (4,751.3–5,229.2)
Turkey 60.4 (57.4–93.4) – 3.4 (2.6–4.0) – 0.2 (0.2–0.2) 860.8 (750.0–947.8)
United Kingdom 489.2 (482.5–505.4) – – 7.8 (7.2–8.0) 2.4 (2.4–2.6) 3,308.5 (3,266.5–3,339.1)
Kruskal–Wallis test p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
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geographic regions such as the Western (11), Nordic (12), 
Mediterranean (13), or Eastern European lands (14).
Work absenteeism due to illness and consecutively number 
of citizens receiving disability benefits were falling steadily over 
most of the past three decades and are about to decline further 
(15). In line with these events, it is anticipated that a contraction 
of compensated absence from work due to illness as evidenced by 
OECD Health Data will become reality. In many countries, this is 
actually driven by policy makers that want to release the pressure 
on businesses. Employers are obliged to financially compensate 
the employee’s absence from work caused by sickness (16). The 
employer’s burden is in many Western European countries shared 
with the municipal or governmental social support funds (17). 
Such schemes may serve as inspiration and alternatives to cutting 
down wage replacement benefits. However, important underlying 
determinant of societal ability and willingness to invest in and 
cope with disability-related absence from work is total health 
expenditure available (18). Evolving landscape of medical spend-
ing has some prominently different features in typical Western 
mature economies and Third World economies among the low-/
middle-income nations (19, 20). In many national accounting 
systems, spending for disability presents a share of the national 
budget devoted to health care (21). So this actually means that 
the long-term priority of health in governmental spending will 
ultimately shape disability/incapacity spending as well. This is 
applicable to both traditional free market economies and the top 
ranked emerging BRICS markets as well (22, 23).
The flat line trend forecast for the public expenditure on inca-
pacity should be taken cautiously. It is more realistic to expect 
downward trend here as well (24).
As previously explained, projected flat trend in public expendi-
ture on incapacity up to 2020 expressed as %GDP share should 
be taken carefully. This value actually refers to joint disability and 
sickness benefits among the OECD member nations (25). High 
level of unpredictable variance leads into suspicion that such 
trend predicted might not realistically reflect the reality (26). 
Absenteeism from work due to illness; number of citizens receiv-
ing social/disability benefits; and compensated absence from work 
due to illness are likely (see Figure 1) to downsize in the long run. 
There are different grounds for this opinion. Some of them might 
relate to recently published long-run projections of longevity 




FigUre 1 | Forecasting analysis for five selected indicators from 1989 to 2013 based on the past data (mean) for selected countries (red lines 
represent observed) and forecasting during next 7 years (blue lines represent forecast): (a) decrease in absenteeism from work due to illness, days 
per employee per year—health for all database (hFa-DB); (B) decrease in people receiving social/disability benefits per 100,000—hFa-DB; (c) 
increase in hospital discharges due to cancer 1989–2013—hFa-DB; (D) decrease in compensated absence from work due to illness—OecD health 
Data; (e) flat trend in public expenditure on incapacity%gDP (disability + sickness benefits)—OecD health Data.
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expectancy leads to higher incidence of incapacity cases due to 
non-communicable illnesses such as dementia (28), traumatism 
(29), and elderly age itself imposing the need for home care 
(30). Another indirect sign of medical demand are prescription 
drugs and associated pharmaceutical spending, which evolves 
differently in the EU-15 and EU post-2004 members (31). This 
downsizing of incapacity spending in Europe ultimately means 
weakened affordability of such social support in many modern 
day societies. Contemporary governments are threatened by the 
lack of financial sustainability of current pension and retirement 
systems (32). Faced with more recent changes such as the global 
recession and migrant crisis, authorities are tempted to prioritize 
resource allocation at the expense of persons with a disability 
(33–35). Actually there is an ongoing opinion that most citizens 
with moderately impaired working ability should return to work 
one way or the other (36). Extensive and elaborate social strate-
gies were derived inclusive of gender adjusted perspective. The 
purpose of these occasionally harsh policies is at least partially to 
compensate the loss of labor market size due to advanced popula-
tion aging. Mandatory legal retirement age was moving in Europe 
from approximately 55 toward 65 in women, while in men, such 
approach preceded for many years (37).
An increase in hospital discharges due to cancer over the 
past 25 years presents quite an increase and thereby a significant 
finding in this study. The prevalence and incidence of most types 
of malignancies tends to increase in most of Europe (38). This 
6Jakovljevic et al. Disability, Absenteeism, Sickness and Cancer
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happens due to a variety of reasons: growing citizen expectations 
(39), earlier diagnostic frontier, medical innovation such as mAbs 
medicines (40), radiation oncology (41), and imaging diagnostics 
advances to name just a few (42). Cancer morbidity and its con-
sequences for the national health systems were relevant for this 
study to study because it is the major driver of disability in most 
European OECD nations.
Based on all projections, it appears that many European 
countries may experience shrinking disability-related social 
costs driven by absenteeism, incapacity benefits, and absence 
compensations from public funds. This trend is not in line 
with ongoing morbidity developments since the global burden 
of disease continues to grow further even in industrialized 
European countries (43). This fact reflects itself to the social 
burden of disability caused by illness expressed in (disability-
adjusted life year unit), which was applied by the Global Burden 
of Disease Project (44). These major risk factors contributing to 
disability were identified to a great extent and determined on 
national and regional level within the comparative risk assess-
ment framework (45). In its essence, cancer morbidity appears 
to remain one of the top drivers of permanent or long-lasting 
disability (46, 47). This is the core reason why we included 
hospital discharges due to cancer as the observed indicator of 
national health expenditure caused by malignant neoplasms. 
Thus, we were capable to reveal long-term hidden morbidity 
trend that is going to shape social burden of incapacity in the 
future of Europe (48).
cOnclUsiOn
What we might be able to see here at a number of European 
OECD nation states presents a contradiction to a certain extent 
and a great challenge. We have clearly growing work load for the 
national health systems attributable to the clinical oncology act-
ing as the major disability contributor. This effectively means that 
large share of these savings on public expenditure shall effectively 
be spent to combat strong cancer morbidity (49). Some of the 
possible strategies to tackle these challenges are heavier invest-
ment into the preventive public health interventions and early 
screening detection of cancer. In return, strengthening efficiency 
of preventive and clinical interventions should make relief on 
absenteeism and disability costs attributable to late diagnosed, 
advanced stage cancer (50).
On another side, we have all signs of falling societal respon-
sibility toward the citizens suffering from diverse kinds of 
incapacity or impaired working ability and independence (51). 
Regardless of malignant tumors, incapacity is driven to a large 
extent by diabetes, COPD (52), traffic and other traumatism (53), 
depression (54), or addiction disorders (55). Citizens suffering 
from any of these causes are likely to experience progressively 
less social support and publicly funded care and work support 
compared to the golden welfare era of previous decades (56). 
This challenge will remain on top of agenda of policymakers in 
OECD and developing countries alike. Such a concerning uneasy 
future is caused by a variety of global socioeconomic develop-
ments worldwide. However, impact of population aging shapes 
the landscape. It implies necessity of labor markets to adapt 
from the historical demographic growth model toward shrink-
ing demographic pyramid of “silver tsunami” (57). How much 
contemporary societies will achieve cost-effective solutions to 
the problem of inclusion and support of disabled citizens yet 
remains to be seen (58). Provided insights into the forthcom-
ing legislative developments up to 2020 in European OECD 
countries should be an impulse toward more ambitious research 
particularly the one targeted toward leading emerging markets 
of tomorrow.
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